TY  -  JOUR
AU  -  Choghakabodi, Parastoo Moradi
AU  -  Pouladzadeh, Mandana
AU  -  Haybar, Habib
AU  -  Keikhaei, Bijan
AU  -  Hossein Nezhad, Khojasteh
AU  -  Jalali Far, Mohammad Ali
AU  -  Torabpour, Masoud
T1  -  Biological whistleblowers for silent myocardial ischemia: diagnostic and prognostic approach
PY  -  2020
Y1  -  2020-07-01
DO  -  10.1701/3407.33924
JO  -  Recenti Progressi in Medicina
JA  -  Recenti Prog Med
VL  -  111
IS  -  7
SP  -  415
EP  -  425
PB  -  Il Pensiero Scientifico Editore
SN  -  2038-1840
Y2  -  2026/04/18
UR  -  http://dx.doi.org/10.1701/3407.33924
N2  -  Summary. Silent myocardial ischemia (SMI) is an aspect of the spectrum of ischemic heart disease ranges from asymptomatic coronary artery disease to severe angina. Considering the progressive increase in SMI prevalence and unreliability of common diagnostic tests, identification of beneficial SMI biomarkers is very critical to rapid diagnosis and effective treatment of disease. The present review aims to analyze the clinical efficiency of well applied and novel biomarkers for diagnosis and outcome prediction of SMI patients. These biomarkers include cTnT, cTnI, hs-cTnT, hs-cTnI, hsCRP, NT-proBNP, sST2, GDF-15, Lp-PLA2, cell-surface receptors, anti-inflammatory cytokines, OPG, leptin, total cholesterol, HDL, LDL, lipoprotein (a), homocysteine, albuminuria, microalbuminuria, and circulating miRNAs. The PubMed database was searched for scientific reports (original articles) using the terms “biomarkers”, “Silent myocardial ischemia”, “cardiac biomarkers”, “inflammatory”, “markers”, “oxidative stress”. A better understanding of various SMI biomarkers provides a better insight into its varied pathophysiology and asymptomatic aspect, and also the routine clinical use of these biomarkers.
ER  -